Exact Sciences announced that it “strongly supports” the American Cancer Society’s update to its colorectal cancer screening guidelines announced today. The new guidelines recommend colorectal cancer screening begin at age 45 for people at average risk of the disease. With more than 20 million Americans age 45-49, Exact Sciences affirmed its commitment to seek U.S. Food and Drug Administration approval for making Cologuard, its noninvasive colorectal cancer screening test, available to those in this population who are at average risk for colorectal cancer. Cologuard is currently available to individuals age 50 and older who are at average risk for colorectal cancer. Exact Sciences will seek to expand the product’s current indication to people age 45 and older who are at an average risk for colorectal cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.